HomeREGULATORY
REGULATORY

Maintain Drug Prices for Duration of Patent Coverage, PhRMA/EFPIA Stress at Chuikyo
(Nov.30.2017)

PhRMA-EFPIA Joint Media Briefing in Tokyo
Japan is the only major country that has a model to regularly cut drug prices even during the patented period, and if it is to follow in the footsteps of other markets in the level of generic shifts, it should also maintain on-patent drug prices as in other markets, US and European trade groups argue ...
(LOG IN FOR FULL STORY)